The creation of retatrutide, a novel dual stimulant targeting both GLP-1 and GIP receptors, represents a complex several-stage synthetic process. Preliminary routes focused on protein portion coupling, utilizing solid-phase production methodologies to build the long amino acid sequence. Subsequen